Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/11/2022 (updated 4/11/2024)
This packet presents Implementation III grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 12/15/2020 (updated 4/3/2024)
This presentation covered recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of SUD and drug overdose. Also, presenters discussed the impact of the pandemic on corrections and the actions of states in response to COVID as it affects those with SUD. Presenters gave an overview of how recovery housing in this context can be developed especially in rural areas.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 7/21/2021 (updated 4/2/2024)
Goals: Increase knowledge of harm reduction principles, strategies, and resources, increase knowledge of managed use, abstinence, and safer use to meet people who use drugs where they are at, provide a safe environment (plenaries and breakouts) to discuss licit and illicit drug use as a multi-faceted phenomenon requiring successful interventions and policies and increase knowledge of stigma as it relates to harm reduction principles and practices.
Posted 10/12/2020 (updated 3/29/2024)
This article discusses findings from a study published in the Journal of Viral Hepatitis which addresses the question of HCV testing frequency in people who inject drugs.
Posted 9/18/2020 (updated 3/29/2024)
The National Alliance of State and Territorial AIDS Directors (NASTAD) hosted the Hepatitis A and Hepatitis B Vaccination Efforts in People Who Inject Drugs webinar last week, September 10, 2020. The session featured Centers for Disease Control and Prevention subject matter experts who discussed the epidemiology of hepatitis A and hepatitis B in people who use and inject drugs and the rationale for the vaccination recommendations. The session also featured several jurisdictions and partner organizations who shared their lessons learned and best practices for reaching and implementing vaccination services in this community.
Posted 11/27/2019 (updated 3/28/2024)
This guide is aimed at people who inject drugs to help reduce some of the problems caused by injecting.
Posted 8/18/2020 (updated 3/28/2024)
This guide was created for harm reduction medical staff and volunteers as a resource about the types of wounds common with injection drug use and also to increase knowledge about treatment modalities for this population. Skin and soft-tissue infections are the most common cause of hospitalization among people who inject drugs.
Posted 11/19/2019 (updated 3/25/2024)
The document provides guidance on how to plan for an outbreak of HIV or HCV among PWID including considerations for developing an outbreak response plan to minimize the impact of the outbreak on the community and stop further transmission. The document also outlines strategies to detect and investigate a possible outbreak.